Beijing Beilu Pharmaceutical Co Ltd

Beijing Beilu Pharmaceutical Co Ltd maintains a relatively strong liquidity position, with a current ratio of 2.4, indicating that it has 2.4 times more current assets than current liabilities. However, the company's liquidity is rated as medium, and its free cash flow is negative at -70.4 million CNY, suggesting that it is spending more on capital expenditures than it is generating in operating cash flow. The company's cash and equivalents are minimal at 1.85 million CNY, and its long-term debt stands at 531.7 million CNY, contributing to a debt-to-equity ratio of 0.24.

In terms of profitability, the company's return on equity (ROE) is 4.11%, and its return on assets (ROA) is 2.77%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The company's net income of 92.7 million CNY is derived from a gross profit of 543 million CNY, with an operating income of 109.6 million CNY. These figures suggest that the company is generating modest returns relative to its asset base and equity.

The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. There is no indication of geographic diversification, and the company's operations appear to be focused on the domestic Chinese market. This concentration increases the company's exposure to local economic and regulatory conditions.

The company's growth trajectory is not clearly defined in the available data, as no specific revenue growth rates or future projections are provided. The company's capital expenditures of 218.9 million CNY suggest a commitment to expanding or upgrading its production capabilities, but the negative free cash flow indicates that this expansion is not yet being funded by internal cash generation.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its ability to fund operations or expansion without external financing. However, the low dilution risk suggests that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders.

Recent events and filings do not provide specific details on the company's strategic direction or major developments. The company's financial statements and disclosures are consistent with a mid-sized pharmaceutical firm operating in a competitive and regulated industry.